直接抗病毒药物时代下丙型肝炎研究面临的挑战

钟劲; 陶万银

doi:10.3969/j.issn.1001-5256.2014.06.001

直接抗病毒药物时代下丙型肝炎研究面临的挑战

DOI: 10.3969/j.issn.1001-5256.2014.06.001

钟劲,
陶万银

中国科学院上海巴斯德研究所

详细信息

中图分类号: R512.63
计量
- 文章访问数: 2440
- HTML全文浏览量: 18
- PDF下载量: 762
- 被引次数: 0
出版历程
- 收稿日期: 2014-04-18
- 出版日期: 2014-06-20

The challenges to hepatitis C research in era of direct antiviral agents

Institut Pasteur of Shanghai, Chinese Academy of Sciences

摘要

摘要: HCV是全球范围内导致慢性病毒性肝炎的重要病原体之一。HCV长期隐匿性感染可能会引发肝纤维化、肝硬化和肝癌等晚期肝病。干扰素和利巴韦林联合用药广泛用于HCV感染的治疗,但这一疗法治疗效果有限,并且具有很强的副作用。HCV小分子直接抗病毒药物(DAA)的出现大大提高了治疗效果,并有望最终完全取代干扰素疗法。然而慢性丙型肝炎治疗进入DAA时代并不意味着丙型肝炎问题已经解决,丙型肝炎研究依然面对诸多挑战。
- 丙型肝炎 /
- 直接抗病毒药物 /
- 综述
Abstract: Hepatitis C virus ( HCV) is an important human pathogen that causes chronic viral hepatitis worldwide. HCV infection, often persistent and asymptomatic, could lead to liver fibrosis /cirrhosis and hepatocellular carcinoma. The interferon /ribavirin therapy has been widely used for treating chronic hepatitis C, but it is not always effective and has strong side effects. The development of small- molecule direct antiviral agents ( DAA) has greatly improved the curing efficiency of chronic hepatitis C therapeutics and will likely replace the interferon- based therapy in the future. However, these developments do not necessarily suggest that the problems of chronic hepatitis C have been completely solved. The HCV research is still facing many challenges in this new DAA era.
- hepatitis C /
- direct antiviral agents /
- review

HTML全文

参考文献(32)

[1]WHO.Guidelines for the screening, care and treatment of persons with hepatitis C infection[M].WHO Press, 2014:5-122.

[2] CHEN YS, LI L, CUI FQ, et al.A sero-epidemiological study onhepatitis C in China[J].Chin J Epidemiol, 2011, 32 (9) :888-891. (in Chinese) 陈园生, 李黎, 崔富强, 等.中国丙型肝炎血清流行病学研究[J].中华流行病学杂志, 2011, 32 (9) :888-891.

[3] SMITH DB, BUKH J, KUIKEN C, et al.Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes:updated criteria and genotype assignment Web resource[J].Hepatology, 2014, 59 (1) :318-327.

[4]THOMAS DL.Global control of hepatitis C:where challenge meets opportunity[J].Nat Med, 2013, 19 (7) :850-858.

[5]MANNS MP, von HAHN T.Novel therapies for hepatitis C-one pill fits all?[J].Nat Rev Drug Discov, 2013, 12 (8) :595-610.

[6]ENOMOTO N, SAKUMA I, ASAHINA Y, et al.Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b.Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region[J].J Clin Invest, 1995, 96 (1) :224-230.

[7]RAO H, WEI L, LOPEZ-TALAVERA JC, et al.Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection[J].J Gastroenterol Hepatol, 2014, 29 (3) :545-553.

[8]SHI X, PAN Y, WANG M, et al.IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population[J].PLoS One, 2012, 7 (5) :e37054.

[9]THOMAS DL, THIO CL, MARTIN MP, et al.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus[J].Nature, 2009, 461 (7265) :798-801.

[10]TANAKA Y, NISHIDA N, SUGIYAMA M, et al.Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C[J].Nat Genet, 2009, 41 (10) :1105-1109.

[11]SUPPIAH V, MOLDOVAN M, AHLENSTIEL G, et al.IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy[J].Nat Genet, 2009, 41 (10) :1100-1104.

[12]GE D, FELLAY J, THOMPSON AJ, et al.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance[J].Nature, 2009, 461 (7262) :399-401.

[13]PROKUNINA-OLSSON L, MUCHMORE B, TANG W, et al.A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus[J].Nat Genet, 2013, 45 (2) :164-171.

[14]LINDENBACH BD, MEULEMAN P, PLOSS A, et al.Cell culturegrown hepatitis C virus is infectious in vivo and can be recultured in vitro[J].Proc Natl Acad Sci U S A, 2006, 103 (10) :3805-3809.

[15]ZHONG J, GASTAMINZA P, CHENG G, et al.Robust hepatitis C virus infection in vitro[J].Proc Natl Acad Sci U S A, 2005, 102 (26) :9294-9299.

[16]WAKITA T, PIETSCHMANN T, KATO T, et al.Production of infectious hepatitis C virus in tissue culture from a cloned viral genome[J].Nat Med, 2005, 11 (7) :791-796.

[17]GOTTWEIN JM, SCHEEL TK, JENSEN TB, et al.Development and characterization of hepatitis C virus genotype 1-7 cell culture systems:role of CD81 and scavenger receptor class B type I and effect of antiviral drugs[J].Hepatology, 2009, 49 (2) :364-377.

[18]LU J, TAO W, LI R, et al.Construction and characterization of infectious hepatitis C virus chimera containing structural proteins directly from genotype 1b clinical isolates[J].Virology, 2013, 443 (1) :80-88.

[19]LI YP, RAMIREZ S, JENSEN SB, et al.Highly efficient fulllength hepatitis C virus genotype 1 (strain TN) infectious culture system[J].Proc Natl Acad Sci U S A, 2012, 109 (48) :19757-19762.

[20]LI YP, RAMIREZ S, GOTTWEIN JM, et al.Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains[J].Proc Natl Acad Sci U S A, 2012, 109 (18) :e1101-e1110.

[21]LU J, XIANG Y, TAO W, et al.A novel strategy to develop a robust infectious hepatitis C virus cell culture system directly from a clinical isolate[J].J Virol, 2014, 88 (3) :1484-1491.

[22]YANG D, ZUO C, WANG X, et al.Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line[J].Proc Natl Acad Sci U S A, 2014, 111 (13) :e1264-e1273.

[23]WU X, ROBOTHAM JM, LEE E, et al.Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation[J].PLoS Pathog, 2012, 8 (4) :e1002617.

[24]HUANG P, ZHANG L, GAO Y, et al.Direct reprogramming of human fibroblasts to functional and expandable hepatocytes[J].Cell Stem Cell, 2014, 14 (3) :370-384.

[25]YU B, HE ZY, YOU P, et al.Reprogramming fibroblasts into bipotential hepatic stem cells by defined factors[J].Cell Stem Cell, 2013, 13 (3) :328-340.

[26]BUKH J.Animal models for the study of hepatitis C virus infection and related liver disease[J].Gastroenterology, 2012, 142 (6) :1279-1287.e3.

[27]DORNER M, HORWITZ JA, DONOVAN BM, et al.Completion of the entire hepatitis C virus life cycle in genetically humanized mice[J].Nature, 2013, 501 (7466) :237-241.

[28]TAO WY, ZHANG Y, ZHONG J.Progress in the development of experimental animal models of HCV infection[J].Infect Dis Info, 2012, 25 (2) :71-74. (in Chinese) 陶万银, 张岩, 钟劲.HCV实验动物模型研究进展[J].传染病信息, 2012, 25 (2) :71-74.

[29]LIANG TJ.Current progress in development of hepatitis C virus vaccines[J].Nat Med, 2013, 19 (7) :869-878.

[30]KHAN AG, WHIDBY J, MILLER MT, et al.Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2[J].Nature, 2014, 509 (7500) :381-284.

[31]KONG L, GIANG E, NIEUSMA T, et al.Hepatitis C virus E2 envelope glycoprotein core structure[J].Science, 2013, 342 (6162) :1090-1094.

[32]LEE YA, FRIEDMAN SL.Reversal, maintenance or progression:What happens to the liver after a virologic cure of hepatitis C?[J].Antiviral Res, 2014, 107C:23-30.

施引文献

资源附件(0)

访问统计